Swiss National Bank Cuts Position in Bruker Corporation $BRKR

Swiss National Bank trimmed its holdings in shares of Bruker Corporation (NASDAQ:BRKR) by 1.5% during the second quarter, HoldingsChannel reports. The institutional investor owned 202,600 shares of the medical research company’s stock after selling 3,000 shares during the quarter. Swiss National Bank’s holdings in Bruker were worth $8,347,000 at the end of the most recent quarter.

Several other large investors also recently made changes to their positions in BRKR. Nisa Investment Advisors LLC raised its stake in shares of Bruker by 377.5% in the 2nd quarter. Nisa Investment Advisors LLC now owns 616 shares of the medical research company’s stock valued at $25,000 after acquiring an additional 487 shares during the period. Huntington National Bank increased its holdings in Bruker by 750.0% in the 2nd quarter. Huntington National Bank now owns 731 shares of the medical research company’s stock valued at $30,000 after purchasing an additional 645 shares in the last quarter. Spire Wealth Management purchased a new position in Bruker in the second quarter valued at about $32,000. Caitong International Asset Management Co. Ltd lifted its stake in shares of Bruker by 1,354.5% during the first quarter. Caitong International Asset Management Co. Ltd now owns 800 shares of the medical research company’s stock worth $33,000 after purchasing an additional 745 shares in the last quarter. Finally, Parallel Advisors LLC boosted its position in shares of Bruker by 63.0% in the second quarter. Parallel Advisors LLC now owns 898 shares of the medical research company’s stock worth $37,000 after buying an additional 347 shares during the period. Institutional investors and hedge funds own 79.52% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages recently commented on BRKR. Wells Fargo & Company dropped their target price on Bruker from $50.00 to $48.00 and set an “overweight” rating on the stock in a report on Wednesday, November 5th. Jefferies Financial Group set a $60.00 price target on shares of Bruker and gave the stock a “buy” rating in a research report on Monday, August 4th. Citigroup lowered their price objective on Bruker from $40.00 to $38.00 and set a “neutral” rating for the company in a report on Monday, August 4th. Rothschild & Co Redburn initiated coverage on shares of Bruker in a report on Thursday, November 20th. They set a “buy” rating and a $60.00 target price on the stock. Finally, TD Cowen lifted their price target on shares of Bruker from $40.00 to $42.00 and gave the company a “hold” rating in a report on Tuesday, November 4th. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, six have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Bruker presently has an average rating of “Moderate Buy” and a consensus price target of $50.25.

Bruker Price Performance

Shares of Bruker stock opened at $47.75 on Friday. The company has a current ratio of 1.61, a quick ratio of 0.70 and a debt-to-equity ratio of 1.31. The company’s 50-day moving average price is $38.89 and its two-hundred day moving average price is $37.62. Bruker Corporation has a 52 week low of $28.53 and a 52 week high of $64.64. The stock has a market cap of $7.26 billion, a PE ratio of 91.83, a price-to-earnings-growth ratio of 5.31 and a beta of 1.26.

Bruker (NASDAQ:BRKR) last announced its earnings results on Monday, November 3rd. The medical research company reported $0.45 EPS for the quarter, beating the consensus estimate of $0.33 by $0.12. The business had revenue of $860.50 million during the quarter, compared to the consensus estimate of $847.40 million. Bruker had a return on equity of 17.89% and a net margin of 2.31%.Bruker’s revenue was down .5% compared to the same quarter last year. During the same period in the prior year, the business posted $0.60 earnings per share. Bruker has set its FY 2025 guidance at 1.850-1.90 EPS. As a group, sell-side analysts anticipate that Bruker Corporation will post 2.69 EPS for the current fiscal year.

Bruker Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, January 2nd. Shareholders of record on Monday, December 8th will be issued a $0.05 dividend. This represents a $0.20 annualized dividend and a dividend yield of 0.4%. The ex-dividend date is Monday, December 8th. Bruker’s dividend payout ratio (DPR) is presently -125.00%.

Insider Activity at Bruker

In other news, Director Cynthia M. Friend sold 3,535 shares of the business’s stock in a transaction that occurred on Friday, September 12th. The shares were sold at an average price of $32.25, for a total transaction of $114,003.75. Following the sale, the director owned 18,016 shares in the company, valued at $581,016. The trade was a 16.40% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director John A. Ornell sold 6,233 shares of the company’s stock in a transaction that occurred on Thursday, November 6th. The shares were sold at an average price of $39.00, for a total transaction of $243,087.00. Following the completion of the sale, the director owned 35,212 shares of the company’s stock, valued at approximately $1,373,268. This trade represents a 15.04% decrease in their position. The SEC filing for this sale provides additional information. Company insiders own 27.30% of the company’s stock.

About Bruker

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.